Study on the Therapeutic Effect of Lifei Xiaoji Wan on Lung Adenocarcinoma in the Early Stage of Ground Glass Nodule (Ia Stage) and Its Effect on Tumor Microenvironment

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study evaluated the relationship between the clinical efficacy, histopathological changes and tumor microenvironment of the pharmacopharmacologic Lifei Xiaoji Wan in the treatment of early stage lung adenocarcinoma, and improved high-level clinical evidence and action targets for the prevention and treatment of early stage lung cancer by traditional Chinese medicine

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• It met the diagnostic criteria of non-small cell lung cancer and was confirmed by pathology, cytology and other relevant examinations.

• Preoperative thin-slice CT showed pure ground glass pulmonary nodules with a size of 10mm-30mm. Intraoperative and postoperative pathology indicated adenocarcinoma, and the tumor stage (TNM) was stage Ia.

• Age: 18-75 years old

• Expected survival \>5 years

• Informed consent and sign informed consent

Locations
Other Locations
China
Mingli Zhao
RECRUITING
Zhengzhou
Contact Information
Primary
Mingli Zhao, MD
13937159120@163.com
0371-66246152
Time Frame
Start Date: 2022-12-01
Estimated Completion Date: 2025-05-31
Participants
Target number of participants: 40
Treatments
Experimental: trial group
The patients in the trial group received routine Western medicine treatments, and oral Lifei Xiaoji Wan (10 pills/time,3 times/day).
Placebo_comparator: control group
The patients in the control group received routine Western medicine treatments.
Sponsors
Leads: Henan University of Traditional Chinese Medicine

This content was sourced from clinicaltrials.gov